secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2026-08-06T11:15:26+00:00
Accession:  0001493152-26-036256
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow acquires global rights to TYRVAYA nasal spray for dry eye disease from Viatris for up to $100M
--------------------------------------------------------------------------------

- $30M cash at closing plus up to $70M in contingent milestone payments tied to TYRVAYA net sales.
- TYRVAYA is first and only FDA-approved nasal spray for dry eye disease; approved in US, China, Taiwan.
- Complements Harrow's VEVYE franchise with different mechanism (stimulates basal tear production vs anti-inflammatory).
- Expected to close in H2 2026, subject to customary closing conditions.
- Harrow expects to fund upfront cash payment from cash on hand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/0001493152-26-036256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer